 | |
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C23H34O2 |
| Molar mass | 342.523 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Cannabidiphorol, theheptyl-homologue ofcannabidiol was identified as a naturalphytocannabinoid and namedcannabidiphorol (CBDP) in 2019.[1] It had previously been reported as a synthetic compound,[2] but was not identified as a natural product prior to 2019. Recently, CBDP has since gained popularity due to it being synthesized and available on a commercial level.[3]
CBDP shows weak antagonism at bothcannabinoid receptors (CB1 andCB2), similar to cannabidiol (CBD). CBD, however, exhibits stronger antagonism at CB2, reaching a 33% maximum response ofSR144528 versus CBDP's 23%.[4]
Both cannabinoids act as weak agonists at theserotonin5-HT1A receptor, contributing to potential anxiolytic effects.[4]
Unlike CBD, CBDP shows no sign ofdopamine D2 receptor agonism.[4]
Unexpectedly, CBDP acts as a positiveallosteric modulator (PAM) at theMOR, enhancingmet-enkephalin signaling by 37%, potentially affecting pain perception.[4]
